Compare CVNA & A Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVNA | A |
|---|---|---|
| Founded | 2012 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.0B | 41.0B |
| IPO Year | 2017 | 1999 |
| Metric | CVNA | A |
|---|---|---|
| Price | $373.60 | $153.73 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 13 |
| Target Price | ★ $409.95 | $160.92 |
| AVG Volume (30 Days) | ★ 3.2M | 2.0M |
| Earning Date | 10-29-2025 | 11-24-2025 |
| Dividend Yield | N/A | ★ 0.66% |
| EPS Growth | N/A | ★ 3.16 |
| EPS | 4.40 | ★ 4.57 |
| Revenue | ★ $18,266,000,000.00 | $6,948,000,000.00 |
| Revenue This Year | $46.87 | $7.12 |
| Revenue Next Year | $26.36 | $5.78 |
| P/E Ratio | $85.19 | ★ $33.59 |
| Revenue Growth | ★ 45.55 | 6.73 |
| 52 Week Low | $148.25 | $96.43 |
| 52 Week High | $413.34 | $160.27 |
| Indicator | CVNA | A |
|---|---|---|
| Relative Strength Index (RSI) | 62.80 | 61.71 |
| Support Level | $308.50 | $148.00 |
| Resistance Level | $340.79 | $160.27 |
| Average True Range (ATR) | 18.89 | 4.39 |
| MACD | 6.98 | 0.44 |
| Stochastic Oscillator | 95.13 | 64.90 |
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage. The foundation of the business is retail vehicle unit sales. This drives the majority of the revenue and allows the company to capture additional revenue streams associated with financing, VSCs, auto insurance and GAP waiver coverage, as well as trade-in vehicles.
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.